|
Leukemia, Myelocytic, Acute
|
0.010 |
PosttranslationalModification
|
disease |
BEFREE |
PAF1 complex interactions with SETDB1 mediate promoter H3K9 methylation and transcriptional repression of <i>Hoxa9</i> and <i>Meis1</i> in acute myeloid leukemia.
|
29774127 |
2018 |
|
Zika Virus Infection
|
0.010 |
Biomarker
|
disease |
BEFREE |
PAF1 was shown to play opposite roles in JEV and ZIKV infections.
|
31199156 |
2019 |
|
Heartburn
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Adsorption parameters of Fe<sub>3</sub>O<sub>4</sub>@SiO<sub>2</sub>@PT towards Au(III) and Pd(II) including initial pH, reaction time, initial concentration of metal ions, effect of acidity and interference of coexisting metal ions were investigated.
|
30447562 |
2019 |
|
Colorectal Carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Biological tests proved that Pd(II) complexes <b>1</b> and <b>2</b> (containing a curcumin derivative) exhibit a strong in vitro antitumor effect against the cells derived from human colorectal carcinoma and the hepatic metastasis of a colorectal carcinoma.
|
28358339 |
2017 |
|
Muscle Rigidity
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
By using the steric hindrance of the nonplanar linker, the connectivity of Zr<sub>6</sub> node can be tuned from 8-c to unusual 4-c. Further, through either one-pot synthesis or postsynthetic linker installation strategies, the connectivity of Zr<sub>6</sub> node can be tuned from 8-c to 10-c by the insertion of a secondary linear dicarboxylate linker, from which not only the temperature-dependent flexibility of the structure can be effectively controlled with enhanced rigidity and thermal stability but also a scaffold for postsynthetic metalation of Pd(II) catalyst for Heck coupling reaction is offered.
|
31497944 |
2019 |
|
Tumor Cell Invasion
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Canertinib combined with Pd(II) complex leads to inhibition of migration and invasion.
|
30825616 |
2019 |
|
Carcinogenesis
|
0.030 |
AlteredExpression
|
phenotype |
BEFREE |
Further, an overexpression of PD2/hPaf1 results in the induction of a transformed phenotype, suggesting its possible involvement in tumorigenesis.
|
17599057 |
2007 |
|
Nephroblastoma
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Germline mutations in the PAF1 complex gene CTR9 predispose to Wilms tumour.
|
25099282 |
2014 |
|
Malignant Neoplasms
|
0.070 |
Biomarker
|
group |
BEFREE |
Here, we concisely describe multifaceted roles of PD2/PAF1 associated with oncogenic transformation and implicate PD2/PAF1 as an attractive target for therapeutic development to combat malignancy.<i>Cancer Res; 78(2); 313-9.©2018 AACR</i>.
|
29311159 |
2018 |
|
Primary malignant neoplasm
|
0.060 |
Biomarker
|
group |
BEFREE |
Here, we concisely describe multifaceted roles of PD2/PAF1 associated with oncogenic transformation and implicate PD2/PAF1 as an attractive target for therapeutic development to combat malignancy.<i>Cancer Res; 78(2); 313-9.©2018 AACR</i>.
|
29311159 |
2018 |
|
Pancreatic carcinoma
|
0.020 |
PosttranslationalModification
|
disease |
BEFREE |
Human RNA polymerase II-association factor 1 (hPaf1/PD2) regulates histone methylation and chromatin remodeling in pancreatic cancer.
|
22046413 |
2011 |
|
Malignant neoplasm of pancreas
|
0.020 |
PosttranslationalModification
|
disease |
BEFREE |
Human RNA polymerase II-association factor 1 (hPaf1/PD2) regulates histone methylation and chromatin remodeling in pancreatic cancer.
|
22046413 |
2011 |
|
Enzyme inhibition disorder
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
In this work, the synthesis, crystal structure, characterization, and enzyme inhibition effects of the novel a series of 2-aminopyridine liganded Pd(II) N-heterocyclic carbene (NHC) complexes were examined.
|
31374523 |
2019 |
|
Carcinogenesis
|
0.030 |
AlteredExpression
|
phenotype |
BEFREE |
Indeed, Paf1 (also known as PD2 or pancreatic differentiation 2) is found to be upregulated in poorly differentiated cancer cells, and such upregulation is involved in cellular transformation or oncogenesis.
|
29023102 |
2017 |
|
Malignant Neoplasms
|
0.070 |
AlteredExpression
|
group |
BEFREE |
Its core subunit, PD2/hPaf1, is amplified and overexpressed in many cancers.
|
17599057 |
2007 |
|
ANOPHTHALMIA AND PULMONARY HYPOPLASIA
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Levels of PAF1 and FOSL1 were increased in PDAC tissues, especially those from smokers, compared with nontumor pancreatic tissue.
|
29864419 |
2018 |
|
Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
Our results indicate that hPaf1/PD2 is overexpressed in OCSCs and maintains the self-renewal of OCSCs through its interaction with OCT3/4; thus, hPaf1/PD2 may be a potential therapeutic target to overcome tumor relapse in OC.
|
28122356 |
2017 |
|
ovarian neoplasm
|
0.010 |
Biomarker
|
disease |
BEFREE |
Our results indicate that hPaf1/PD2 is overexpressed in OCSCs and maintains the self-renewal of OCSCs through its interaction with OCT3/4; thus, hPaf1/PD2 may be a potential therapeutic target to overcome tumor relapse in OC.
|
28122356 |
2017 |
|
Malignant neoplasm of ovary
|
0.010 |
Biomarker
|
disease |
BEFREE |
Our results indicate that hPaf1/PD2 is overexpressed in OCSCs and maintains the self-renewal of OCSCs through its interaction with OCT3/4; thus, hPaf1/PD2 may be a potential therapeutic target to overcome tumor relapse in OC.
|
28122356 |
2017 |
|
Carcinoma, Ovarian Epithelial
|
0.010 |
Biomarker
|
disease |
BEFREE |
Our results indicate that hPaf1/PD2 is overexpressed in OCSCs and maintains the self-renewal of OCSCs through its interaction with OCT3/4; thus, hPaf1/PD2 may be a potential therapeutic target to overcome tumor relapse in OC.
|
28122356 |
2017 |
|
Malignant Neoplasms
|
0.070 |
Biomarker
|
group |
BEFREE |
Our results showed that the Pd(II) complex was more cytotoxic to cancer cells than noncancer cell lines and caused cell death through apoptotic pathways.
|
28657910 |
2017 |
|
Primary malignant neoplasm
|
0.060 |
Biomarker
|
group |
BEFREE |
Our results showed that the Pd(II) complex was more cytotoxic to cancer cells than noncancer cell lines and caused cell death through apoptotic pathways.
|
28657910 |
2017 |
|
Peroxisomal Disorders
|
0.010 |
Biomarker
|
group |
BEFREE |
Per6p has significant overall sequence similarity with the human peroxisome assembly factor PAF-1, a protein that is defective in certain patients suffering from the peroxisomal disorder Zellweger syndrome, and with car1, a protein required for peroxisome biogenesis and caryogamy in the filamentous fungus Podospora anserina.
|
8628321 |
1996 |
|
Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
Pt(II) and Pd(II) complexes with a thiazoline derivative ligand: Synthesis, structural characterization, antiproliferative activity and evaluation of pro-apoptotic ability in tumor cell lines HT-29 and U-937.
|
31689624 |
2020 |
|
Zellweger Syndrome
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
Recently, the use of experimental models led to the identification of a gene encoding for a peroxisomal membrane protein (PAF-1) in which a mutation was associated with the altered phenotype in a complementation group of the Zellweger syndrome (paradigm of these diseases).
|
8507691 |
1993 |